Delisting Risk Due to Disclaimer of Opinion; Objection Filed, Improvement Plan Due May 12
Celestra received a disclaimer of opinion on 2025 financial statements due to audit scope limitation and going concern uncertainty, triggering delisting grounds
The exchange plans to review combined with the 2024 adverse opinion reason; Celestra filed an objection on April 28, 2026
After the cure period ended on April 17, 2026, the company must submit an improvement plan execution report within 15 business days (by May 12, 2026)
The exchange will convene a listing review committee within 20 business days from the submission date and notify the delisting decision within 3 business days thereafter
KOSDAQ Filing Information
Filing: Other Market Notice (Receipt of Objection Application Related to Delisting)